ProCE Banner Activity

My Thoughts on the New FDA Guidance for Pembrolizumab and Atezolizumab in Bladder Cancer

Clinical Thought
Are you aware of the recent FDA alert limiting first-line use of immune checkpoint inhibitors in patients with urothelial carcinoma? In this commentary, I explore the reasons for and the ramifications of this change.

Released: August 28, 2018

Expiration: August 27, 2019

No longer available for credit.

Share

Faculty

Matthew I. Milowsky

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Matthew I. Milowsky, MD

Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Matthew I. Milowsky, MD, has disclosed that he has received funds for research support from Acerta, BioClin, Bristol-Myers Squibb, Cerulean, Incyte, Innocrin, Inovio, MedImmune, Merck, Mirati, Pfizer, Roche/Genentech, Seattle Genetics, and X4 Pharma.